Proteins from Sacha inchi (SI) have been widely known for their health-benefiting properties. This study aimed to investigate the different protein isolates obtained from oil press-cakes of Thai and Peru SI. The protein content and protein recovery of Thai and Peru SI were estimated to be 93.27, 90.67%, and 49.15, 59.32%, respectively. The protein patterns of the Thai and Peru SI samples analyzed by SDS-PAGE showed glycoprotein as a major protein, with a molecular weight of 35 kDa. Both protein isolates (PI) showed water and oil holding capacities in the range of 2.97−3.09 g/g sample and 2.75−2.88 g/g sample, respectively. The emulsifying properties of the PI from Thai SI were higher than those of Peru (p < 0.05), while the foaming properties were not analogous to the emulsion properties. The Thai SI sample showed lower digestibility up to 120 min of in vitro digestion time than that of the Peru SI sample (p < 0.05). However, simulated in vitro pepsin digestion of Thai and Peru Si samples displayed hydrolyzed protein bands compared to trypsin digestion, which showed no protein patterns in both SI samples on a 4−20% gradient gel. These results suggest that the protein isolates from Thai and Peru SI exhibit marked variations in physical and techno-functional properties and have a high potential to be employed as plant-based protein additives for future non-animal-based protein-rich foods.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265265 | PMC |
| http://dx.doi.org/10.3390/foods11131869 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
N Engl J Med
November 2024
From the Hope Clinic of the Emory University School of Medicine, Decatur (C.F.K.), and Grady Health System (C.F.K.), and the Division of Infectious Diseases, Emory University-Ponce de Leon Center Clinical Research Site, HIV/AIDS Clinical Trials Unit (V.D.C.), Atlanta - all in Georgia; the Divisions of Pediatric and Adult Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore (A.L.A.); Be Well Medical Center, Berkley, MI (P.B.); the Department of Medicine, University of California, San Diego, San Diego (J.B.), the Department of Medicine, University of California, Los Angeles (J.C.), Ruane Clinical Research (P.J.R.), and Drew Center for AIDS Research, Education, and Services, Charles R. Drew University (L.Y.S.), Los Angeles, Optimus Medical Group/StudyOps, San Francisco (S.H.), Mills Clinical Research, West Hollywood (A.M.), Bios Clinical Research, Palm Springs (P.S.), and Gilead Sciences, Foster City (S.C., R.E., P.W., R.S., L.B.B., C.C.C., M.D., J.M.B.) - all in California; Central Texas Clinical Research, Austin (C. Brinson), and Crofoot MD Clinic and Research Center, Houston (G.C.) - both in Texas; the Department of Infectious Diseases, Louisiana State University Health Sciences Center-New Orleans, New Orleans (M.C.); Howard Brown Health (C.C.) and the Division of Infectious Diseases, University of Illinois Health Sciences (R.M.N.) - both in Chicago; the Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami (S.D.-L.), Therafirst Medical Center, Fort Lauderdale (A.L.), Midway Immunology and Research Center, Fort Pierce (M.R.), and CAN Community Health, Sarasota (T.S.) - all in Florida; the Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN (A.G.); Washington Health Institute, Washington, DC (T.H.); Fenway Health Medical Clinic, Boston (K.H.M.); Philadelphia FIGHT Community Health Centers-Jonathan Lax Treatment Center, Philadelphia (K.M.); the Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham (O.T.V.G.); the Section of Infectious Diseases, Yale School of Medicine, New Haven, CT (O.O.); Centro Ararat, San Juan, Puerto Rico (M.A.-Q.); the HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University (A.A.), and the Institute of HIV Research and Innovation-Pribta Tangerine Clinic (N.P.) - both in Bangkok; Complexo Hospitalar Universitário Professor Edgard Santos, Salvador (C. Brites), Universidade Federal de São Paulo (R.S.D.), Centro de Referência e Treinamento DST/AIDS-SP (J.V.M.), and Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (R.V.), São Paulo, Fundação Oswaldo Cruz-Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro (B.G.), Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus (M.L.), and the Infectious Diseases Service, Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Fundación Huésped (P.C.) and Hospital General de Agudos José María Ramos Mejía (M.H.L.) - both in Buenos Aires; Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos (J.A.G.-C., J.S.) and Via Libre (J.G.V.), Lima, and Asociación Civil Selva Amazónica, Iquitos (J.C.H.) - all in Peru; Desmond Tutu Health Foundation, Cape Town (R.K.), Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg (N.N.), and the Aurum Institute-Pretoria Clinical Research Site, Pretoria (Z.Z.) - all in South Africa; Centro de Investigacion Farmaceutica Especializada de Occidente, Guadalajara, Mexico (A.P.R.); and Gilead Sciences, Cambridge, United Kingdom (C.D.).
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear.
Methods: In this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants in a 2:1 ratio to receive subcutaneous lenacapavir every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF).
Global multi-societies endorsement of the MAFLD definition.
Ann Hepatol
January 2024
Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Minia University, Cairo, Egypt.; Egyptian MAFLD research group (EMRG).
Article Synopsis
- Researchers studied strokes from 1990 to 2021 to understand how many people get them and how they are affected around the world.
- In 2021, strokes caused about 7.3 million deaths and were a major cause of health problems, especially in specific regions like Southeast Asia and Oceania.
- There are differences in stroke risks based on where people live and their age, and some areas actually saw more strokes happening since 2015.
Identifying priority sites for whale shark ship collision management globally.
Sci Total Environ
July 2024
Marine Research and Conservation Foundation, Somerset, UK; Environmental Science Program, Department of Biological and Environmental Sciences, College of Arts and Sciences, Qatar University, Doha, Qatar.
The expansion of the world's merchant fleet poses a great threat to the ocean's biodiversity. Collisions between ships and marine megafauna can have population-level consequences for vulnerable species. The Endangered whale shark (Rhincodon typus) shares a circumglobal distribution with this expanding fleet and tracking of movement pathways has shown that large vessel collisions pose a major threat to the species.
View Article and Find Full Text PDFThis article - Recommendations and Guidelines of Integrative Medicine (IM) for COVID-19 Care - was one of the outcomes from an Asia-Pacific Economic Cooperation (APEC) Project (Integrative Medicine (IM) and COVID -19 Care) during the time between May 2022 and March 2023. With the efforts from care providers, researchers, health policy makers and healthcare administrative leaders among APEC economies, the purpose of this file was to provide comprehensive IM systems for COVID-19 care as recommendations and suggestive guidelines including care methods, tools, procedures, symptom conditions and targets selections, and points need to be considered during care applications. All cited COVID-19 care practices have confirmed their efficacy and usefulness either used alone or combined with conventional medicine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!